Kidney Cancer

Researchers at Keck Medicine of USC are part of a national, multisite clinical trial to evaluate a minimally invasive water vapor system that uses steam to treat prostate cancer.

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney cancer, according to results of a phase 1 trial.

Higher urinary arsenic levels were associated with kidney damage among U.S. adults in a study that assessed data from the National Health and Nutrition Examination Survey.

People with cancer should receive “current, accurate and digestible” information that allows them to be “active stakeholders” in their cancer journey, according to NCI Director W. Kimryn Rathmell, MD, PhD, MMHC.

It’s only the beginning.

In 2024, the treatment landscape for kidney cancer evolved, with new breakthroughs in combination therapies, new challenges and an emphasis on addressing disparities in care.

Belzutifan significantly improved PFS and objective response compared with everolimus for patients with advanced renal cell carcinoma, according to results of a randomized phase 3 trial.

Combining gut microbiome manipulation with immunotherapy and tyrosine kinase inhibitor therapy conveyed clinical benefit for patients with metastatic renal cell carcinoma, results of a randomized phase 1 trial showed.

The addition of nivolumab to low-dose tivozanib did not improve PFS for patients with advanced renal cell carcinoma, according to data from the agent’s manufacturer.

Geographic disparities in the availability of cancer clinical trials throughout the United States have worsened over time, according to study data published in JAMA Network Open.